ABBVIE INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 166.4 USD | +1.26% |
|
+3.53% | +7.39% |
| 17/05 | Cantor Fitzgerald Initiates AbbVie at Overweight Rating With $200 Price Target | MT |
| 17/05 | ANALYST RECOMMENDATIONS : Walmart, Netflix, Abbvie, Delta... |  |
Presenter SpeechTimothy Anderson (Analysts)Hey, guys. I'm Timothy Anderson. I'm the large-cap ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease.
Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Sector
Pharmaceuticals
Calendar
26/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
166.4
USD
Average target price
182.3
USD
Spread / Average Target
+9.52%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +7.39% | 294B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B | |
| -0.52% | 162B |
- Stock Market
- Equities
- ABBV Stock
- News AbbVie Inc.
- Transcript : AbbVie Inc. Presents at 3rd Annual Wolfe Research Virtual Healthcare Conference 2021, Nov-17-2021 09
